Overview

A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults

Status:
RECRUITING

Trial end date:
2026-01-16

Target enrollment:

Participant gender:

Summary

The aim of this study is to evaluate the safety, reactogenicity and immunogenicity of the Flu Pandemic messenger RNA (mRNA) vaccine (including dose-finding and dose-confirmation) administered in healthy adults 18 to 85 years of age.

Phase:

PHASE1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Influenza Vaccines